GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Cyclically Adjusted FCF per Share

Amgen (BUE:AMGN) Cyclically Adjusted FCF per Share : ARS780.75 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Amgen Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Amgen's adjusted free cash flow per share for the three months ended in Mar. 2025 was ARS9,655.418. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS780.75 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Amgen's average Cyclically Adjusted FCF Growth Rate was 5.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Amgen was 25.30% per year. The lowest was 8.10% per year. And the median was 16.40% per year.

As of today (2025-05-28), Amgen's current stock price is ARS10975.00. Amgen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was ARS780.75. Amgen's Cyclically Adjusted Price-to-FCF of today is 14.06.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 27.59. The lowest was 13.20. And the median was 19.00.


Amgen Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Amgen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Cyclically Adjusted FCF per Share Chart

Amgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.96 284.07 530.15 1,615.72 697.49

Amgen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 614.06 768.66 709.36 697.49 780.75

Competitive Comparison of Amgen's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted Price-to-FCF falls into.


;
;

Amgen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=9655.418/134.9266*134.9266
=9,655.418

Current CPI (Mar. 2025) = 134.9266.

Amgen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 183.446 100.684 245.836
201509 172.540 100.392 231.894
201512 158.437 99.792 214.218
201603 169.003 100.470 226.962
201606 220.976 101.688 293.206
201609 256.933 101.861 340.337
201612 306.902 101.863 406.520
201703 230.631 102.862 302.524
201706 239.165 103.349 312.240
201709 393.980 104.136 510.473
201712 375.982 104.011 487.736
201803 364.439 105.290 467.022
201806 361.819 106.317 459.184
201809 879.434 106.507 1,114.099
201812 873.215 105.998 1,111.531
201903 539.829 107.251 679.132
201906 465.101 108.070 580.686
201909 1,489.657 108.329 1,855.400
201912 1,164.434 108.420 1,449.114
202003 1,040.758 108.902 1,289.477
202006 1,551.914 108.767 1,925.160
202009 2,037.504 109.815 2,503.426
202012 1,379.558 109.897 1,693.762
202103 1,502.367 111.754 1,813.882
202106 1,435.752 114.631 1,689.948
202109 1,866.397 115.734 2,175.903
202112 2,257.055 117.630 2,588.949
202203 1,923.343 121.301 2,139.390
202206 1,886.739 125.017 2,036.297
202209 3,639.044 125.227 3,920.926
202212 3,597.619 125.222 3,876.438
202303 1,321.896 127.348 1,400.565
202306 8,576.536 128.729 8,989.470
202309 8,169.837 129.860 8,488.623
202312 969.600 129.419 1,010.860
202403 3,607.346 131.776 3,693.588
202406 18,381.751 132.554 18,710.796
202409 29,058.643 133.029 29,473.174
202412 41,072.089 133.157 41,617.888
202503 9,655.418 134.927 9,655.418

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Amgen  (BUE:AMGN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Amgen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=10975.00/780.75
=14.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 27.59. The lowest was 13.20. And the median was 19.00.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Amgen Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Amgen's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Industry
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.